Literature DB >> 20601195

Can controlled cellular reprogramming be achieved using microRNAs?

Xiaoyan Sun1, Xiaobing Fu, Weidong Han, Yali Zhao, Huiling Liu.   

Abstract

Since a technique was reported for generating induced pluripotent stem cells (iPSCs), various groups worldwide have reprogrammed human and mouse somatic cells into iPSCs using a range of techniques and pluripotency genes. Progress in iPSC research has opened up a novel avenue in autologous regenerative medicine, whereby patient-specific pluripotent cells could potentially be derived from adult somatic cells. However, several limitations currently prohibit their use in clinical settings, including the viral DNA delivery system and the exogenous overexpression of pluripotency genes. New strategies are therefore needed to ensure the safe and efficient production of iPSCs, and to guide their differentiation into the desired lineages required to repair damaged tissue and treat disease. Here, we present an overview of recent research into cellular reprogramming. We focus on the feasibility of microRNA-based strategies for reprogramming somatic cells into pluripotent stem cells, thus obviating the need to introduce viruses or DNA into donor cells, and therefore ameliorating the risks associated with reprogramming techniques. In light of the critical roles of microRNAs in maintaining the pluripotent state and in regulating cell-lineage specification and epigenetic modifications of chromatin, we also discuss the potential role of microRNAs as candidates for controlled cellular reprogramming and induction of cell fate conversion beyond lineages without reversion to a pluripotent state. Further research into the microRNAs involved in iPSC reprogramming and their potential roles in controlled cellular reprogramming will add another dimension to our understanding of the molecular mechanisms involved in cellular reprogramming.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601195     DOI: 10.1016/j.arr.2010.06.002

Source DB:  PubMed          Journal:  Ageing Res Rev        ISSN: 1568-1637            Impact factor:   10.895


  8 in total

1.  Differential expression of speckled POZ protein, SPOP: putative regulation by miR-145.

Authors:  Chiu-Jung Huang; Hsing-Yu Chen; Wan-Yi Lin; Kong Bung Choo
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

Review 2.  Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.

Authors:  Lei Cao; Lan Tan; Teng Jiang; Xi-Chen Zhu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

Review 3.  Liposomes in tissue engineering and regenerative medicine.

Authors:  Nelson Monteiro; Albino Martins; Rui L Reis; Nuno M Neves
Journal:  J R Soc Interface       Date:  2014-12-06       Impact factor: 4.118

4.  Tinkering with transcription factors uncovers plasticity of somatic cells.

Authors:  Judi L Azevedo; Ricardo A Feldman
Journal:  Genes Cancer       Date:  2010-11

Review 5.  Epigenetics in the development, modification, and prevention of cardiovascular disease.

Authors:  Thomas F Whayne
Journal:  Mol Biol Rep       Date:  2014-09-10       Impact factor: 2.316

6.  The PluriNetWork: an electronic representation of the network underlying pluripotency in mouse, and its applications.

Authors:  Anup Som; Clemens Harder; Boris Greber; Marcin Siatkowski; Yogesh Paudel; Gregor Warsow; Clemens Cap; Hans Schöler; Georg Fuellen
Journal:  PLoS One       Date:  2010-12-10       Impact factor: 3.240

Review 7.  Engineering skeletal muscle tissue--new perspectives in vitro and in vivo.

Authors:  Dorothee Klumpp; Raymund E Horch; Ulrich Kneser; Justus P Beier
Journal:  J Cell Mol Med       Date:  2010-11       Impact factor: 5.310

8.  MEK and TGF-beta Inhibition Promotes Reprogramming without the Use of Transcription Factor.

Authors:  Jan Vrbsky; Tamas Tereh; Sergiy Kyrylenko; Petr Dvorak; Lumir Krejci
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.